GenMont Biotech vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how GenMont Biotech (3164) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees GenMont Biotech as the less overvalued of the two: GenMont Biotech trades at TWD 16.60 versus a fair value of TWD 11.34 (-32%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
GenMont Biotech
3164.TW · TWD · Health Care
-32%
upside to fair value
overvalued
PriceTWD 16.60
Fair ValueTWD 11.34
Quality69/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
GenMont BiotechVertex Pharmaceuticals
Valuation
24.6×P/E (TTM)28.8×
3.58×P/S (TTM)10.06×
1.05×P/B6.59×
12.9×EV/EBITDA23.8×
—PEG1.72×
4.9%Dividend yield—
TWD 0.80Dividend per share—
Profitability
11%Net margin36%
-8%Operating margin38%
3%Return on equity24%
1%Return on assets12%
Growth
-10%Revenue growth (YoY)8%
2.9%Avg. growth/yr (3Y)10.6%
4.3%Avg. growth/yr (5Y)14.2%
Balance & size
0.03×Debt / equity0.03×
$43MMarket cap$123B
healthyGrowth qualityhealthy
Vertex Pharmaceuticals leads: 4 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
GenMont Biotechof which business quality 69 · market factors 44Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
32
72
Quality GrowthAre margins and returns improving?
40
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
100
58
Low VolatilityCalm price path (market factor)
100
86
MomentumPrice trend over the last 3–12 months (market factor)
26
54
52W MomentumDistance to the 52-week high (market factor)
12
59
Net IssuanceBuybacks instead of dilution
100
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
GenMont Biotech
DCF ModelsTWD 12.90
Earnings-BasedTWD 5.13
Dividend DiscountTWD 9.08
MultiplesTWD 11.71
Asset-BasedTWD 10.37
Growth DCFTWD 10.06
Economic ProfitTWD 8.07
Growth EarningsTWD 11.74
22 of 25 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
18 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
GenMont Biotech
Bear TWD 8.48Fair Value TWD 11.34Bull TWD 14.19
TWD 16.60 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
GenMont Biotech · Health Care
Quality score69 · Top 25%
Fair value upside-32% · below median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-44% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees GenMont Biotech as the less overvalued of the two: GenMont Biotech trades at TWD 16.60 versus a fair value of TWD 11.34 (-32%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
